Periprosthetic joint infection: from biofilm pathophysiology to precision management—a comprehensive clinical review
Frontiers in Cellular and Infection Microbiology · 19.11.2026 · 16
DOI: 10.3389/fcimb.2026.1980967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 19.11.2026. Verfasst von Nan Yang und 9 weiteren Autor:innen. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Periprosthetic joint infection (PJI) is among the most serious complications of total joint arthroplasty, with incidence of approximately 1%–2% after primary procedures and rising absolute numbers driven by aging populations and growing surgical volumes. Its pathophysiological cornerstone is bacterial biofilm formation on implant surfaces, which confers tolerance to antimicrobials and host immunity through extracellular polymeric substance barriers, metabolic dormancy, and persister cells. This narrative review synthesizes evidence across the PJI continuum—epidemiology, risk stratification, biofilm pathophysiology, diagnostics, treatment, and emerging technologies—explicitly stratifying the cited evidence by maturity, from in vitro studies to randomized trials. We review the evolving pathogen spectrum, including methicillin-resistant Staphylococcus aureus and multidrug-resistant gram-negative organisms. Synovial calprotectin, metagenomic next-generation sequencing, and artificial intelligence are appraised alongside conventional culture and serology, with attention to their limitations. Treatment strategies—debridement, antibiotics, and implant retention (DAIR), one-stage and two-stage exchange, and permanent articulating spacers—are discussed in relation to infection chronicity, host status, and pathogen phenotype. Emerging anti-biofilm therapeutics, including monoclonal antibodies, bacteriophages, photothermal nano-agents, and antimicrobial peptides, are categorized by evidence level and translational readiness. Finally, we identify evidence gaps and propose research priorities—standardized biofilm models, multicenter registries, and rigorously designed trials—needed before precision management of PJI can be realized in routine practice.
Zitieren
APA
Yang, N., Zhang, C., Liu, Y., Wu, X., Yu, J., Zhao, Y., Du, X., Zhang, S., Wang, J., & Zhang, Q. (2026). Periprosthetic joint infection: from biofilm pathophysiology to precision management—a comprehensive clinical review. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1980967
Vancouver
Yang N, Zhang C, Liu Y, Wu X, Yu J, Zhao Y, et al. Periprosthetic joint infection: from biofilm pathophysiology to precision management—a comprehensive clinical review. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1980967
BibTeX
@article{Yang2026,
author = {Yang, Nan and Zhang, Cong and Liu, Yan and Wu, Xia and Yu, Jianxue and Zhao, Yalin and Du, Xinxin and Zhang, Shuai and Wang, Jing and Zhang, Qian},
title = {Periprosthetic joint infection: from biofilm pathophysiology to precision management—a comprehensive clinical review},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1980967}
}
EUVIMED